Keyphrases
Atorvastatin
100%
Statins
100%
Metabolic Profiling
100%
Intervention Studies
100%
Disease Intervention
100%
End-organ Disease
100%
Profile Data
100%
Confidence Interval
42%
Lipoprotein Subclasses
42%
Randomized Clinical Trial
28%
Fatty Acids
28%
Cholesterol
14%
Placebo
14%
Placebo-controlled
14%
Fatty Acid Composition
14%
Low Density
14%
Response Pattern
14%
Once-daily
14%
Metabolic Pathway
14%
Lipoproteins
14%
Molecular Changes
14%
Lipid Composition
14%
Nuclear Magnetic Resonance
14%
Cholesterol Levels
14%
Metabolomics
14%
Cardiovascular Risk
14%
Apolipoprotein B (Apo B)
14%
Lipid-lowering
14%
Study within a Trial
14%
Low-density Lipoprotein Cholesterol (LDL-C)
14%
Clinical Trial Data
14%
Isoprenoids
14%
Heterogeneous Response
14%
Rate-limiting Enzyme
14%
HMG-CoA Reductase
14%
Low Cholesterol
14%
Remnant Cholesterol
14%
Effect Magnitude
14%
High-density Lipoprotein Subclasses
14%
Pharmacology, Toxicology and Pharmaceutical Science
Statin (Protein)
100%
Intervention Trial
100%
Pravastatin
100%
Terminal Illness
100%
Lipoprotein
57%
Fatty Acid
42%
Placebo
28%
Randomized Clinical Trial
28%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
14%
Low Density Lipoprotein Cholesterol
14%
Cardiovascular Risk
14%
Isoprenoid
14%
Apolipoprotein B
14%
High Density Lipoprotein
14%
Hydroxymethylglutaryl Coenzyme A Reductase
14%